MedTrace Logo

Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

NCT07021937 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-06-15

No results posted yet for this study

Summary

Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.

Conditions

  • Obesity/Therapy

Interventions

DRUG

Semaglutide 1.7mg subcutaneous

Semaglutide subcutaneous max dose of 1.7mg over 24 or 32 weeks of active treatment

DRUG

Placebo

Placebo saline solution subcutaneous

Sponsors & Collaborators

  • University of Minnesota

    collaborator OTHER

  • The Metis Foundation

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Allison Shapiro, PhD, MPH · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2031-04-30
Completion
2031-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07021937 on ClinicalTrials.gov